RxElite, Inc.
RXEI · OTC
12/31/2007 | 9/30/2006 | 9/30/2005 | 9/30/2004 | |
|---|---|---|---|---|
| Revenue | $3 | $1 | $1 | $1 |
| % Growth | 139% | 21.7% | 15.7% | – |
| Cost of Goods Sold | $3 | $0 | $0 | $0 |
| Gross Profit | $0 | $1 | $1 | $1 |
| % Margin | 5.1% | 63.1% | 53.5% | 100% |
| R&D Expenses | $3 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $9 | $1 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12 | $1 | $1 | $0 |
| Operating Income | $12 | $0 | $0 | $1 |
| % Margin | 436.8% | 12.2% | 3.7% | 100% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$1 |
| Pre-Tax Income | -$17 | $0 | $0 | $0 |
| Tax Expense | $5 | $0 | $0 | $0 |
| Net Income | -$17 | $0 | -$0 | -$0 |
| % Margin | -610.5% | 8% | -3.7% | -4.1% |
| EPS | -0.27 | 0.009 | -0.004 | 0 |
| % Growth | -3,100% | 350% | – | – |
| EPS Diluted | -0.27 | 0.009 | -0.004 | 0 |
| Weighted Avg Shares Out | 62 | 10 | 10 | 0 |
| Weighted Avg Shares Out Dil | 62 | 10 | 10 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$16 | $0 | -$0 | $1 |
| % Margin | -585.6% | 13.4% | -3% | 100% |